In short
Currently, there is one ongoing clinical trial investigating treatment approaches for pulmonary congestion in patients with acute heart failure. This trial is evaluating different medication strategies to determine the most effective emergency treatment for fluid buildup in the lungs that causes breathing difficulties.
Clinical trial locations
Comparison of Furosemide, Nitrates, or Their Combination for Initial Treatment of Pulmonary Congestion in Patients with Acute Heart Failure
This clinical trial is taking place in Denmark and focuses on finding the most effective emergency treatment for patients experiencing pulmonary congestion due to acute heart failure. Pulmonary congestion occurs when fluid builds up in the lungs, making it difficult to breathe. This condition can develop suddenly or worsen over several days, requiring immediate medical attention.
Main inclusion criteria: Participants must be at least 18 years old and experiencing sudden or worsening difficulty breathing. They need to have a systolic blood pressure of at least 100 mmHg and show signs of low oxygen levels, with oxygen saturation below 94% or requiring oxygen support. Additionally, patients must show signs of fluid buildup in the body, such as swelling in the legs or feet, crackling sounds in the lungs, or other indicators of fluid retention.
Main exclusion criteria: The trial cannot include patients with severe kidney problems requiring dialysis, those who have had a heart attack within the past 30 days, or individuals with severe liver disease. Pregnant or breastfeeding women are not eligible, nor are patients with allergies to the study medications. Other exclusions include participation in another clinical trial, uncontrolled high blood pressure, severe lung disease affecting breathing, and unstable mental health conditions that might interfere with following study procedures.
Trial focus and goals: The study aims to compare three different treatment approaches for pulmonary congestion. The first approach uses only loop-diuretics, specifically furosemide, which helps remove excess fluid from the body by increasing urination. The second approach uses only vasodilation with nitrates, which relax and widen blood vessels to reduce the workload on the heart. The third approach combines both medications to potentially provide the benefits of both treatments. Treatment begins within three hours of hospital admission, and participants are closely monitored to assess how they respond to each strategy. The primary goal is to evaluate how many days participants remain alive and outside the hospital until day 30.
Investigational drugs: The trial is testing furosemide, a medication that makes the kidneys produce more urine to remove excess fluid and reduce swelling and fluid buildup in the lungs. It also tests nitrates, specifically Isoket, which help widen blood vessels to improve blood flow and reduce pressure in the lung blood vessels, making it easier for the heart to pump blood. The combination of both furosemide and nitrates is also being evaluated to determine if using both medications together provides better results than using either one alone.
Summary
Currently, there is one clinical trial investigating treatment options for pulmonary congestion in patients with acute heart failure. This trial, located in Denmark, represents an important effort to determine the most effective emergency treatment strategy for this serious condition. The study focuses on comparing three different medication approaches: loop-diuretics alone, nitrates alone, or a combination of both treatments. The concentration of this research on optimizing initial emergency treatment reflects the critical nature of pulmonary congestion and the need for rapid, effective intervention. By evaluating these different treatment strategies, the trial aims to provide evidence-based guidance for healthcare providers managing patients who present with fluid buildup in the lungs due to heart failure.
